Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Xavier Harrison

Physician Assistant, Medical Huntersville, NC Physician Assistant

NPI 1477582807 CMS profile 10866656

9930 Kincey Ave Ste 165, Huntersville, NC 28078

Open in the dashboard

General payments

$15,302

618 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Xavier Harrison of Huntersville, NC is reported in the CMS Open Payments database as having received $15,302 across 618 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,078 139
2024 General $2,740 104
2023 General $2,798 125
2022 General $2,752 126
2021 General $2,934 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Xavier Harrison
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Xavier Harrison were reported at $4,078. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Xavier Harrison Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,934 $156 $41–$563 $132
2022 $2,752 $185 $55–$649 $149
2023 $2,798 $199 $58–$717 $160
2024 $2,740 $206 $62–$740 $164
2025 $4,078 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $4,086 93 payments
  2. AstraZeneca Pharmaceuticals LP $745 37 payments
  3. Pfizer Inc. $698 35 payments
  4. Incyte Corporation $645 26 payments
  5. Janssen Biotech, Inc. $608 22 payments
  6. Genzyme Corporation $508 20 payments
  7. AbbVie, Inc. $419 15 payments
  8. Genentech USA, Inc. $411 21 payments
  9. Eisai Inc. $395 19 payments
  10. Daiichi Sankyo Inc. $373 16 payments
  11. Other $6,415 314 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,396 586 payments
  2. Long term medical supply or device loan $2,728 29 payments
  3. Education $178 3 payments
Products named General payments · program years 2021–2025
  1. KISQALI $3,189 57 payments
  2. JAKAFI $534 23 payments
  3. Lenvima $376 18 payments
  4. XTANDI $344 15 payments
  5. KEYTRUDA $301 15 payments
  6. VENCLEXTA $273 9 payments
  7. SARCLISA $270 9 payments
  8. TALVEY $250 6 payments
  9. LIBTAYO $242 12 payments
  10. VERZENIO $232 11 payments
  11. Other $12,205 594 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

15

Median for Physician Assistant: 241

Drug cost

$329

Median for Physician Assistant: $4,110

Branded share of claims

0%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 15 $329

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 133 billing codes

Paid by Medicare

$505,783

Of which drugs: $425,617

Medicare patients

294

Average age 75

Services billed

47,651

184 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Chronic kidney disease 37%
Diabetes 35%
Osteoporosis 29%
Cancer 28%
Depression 25%
Ischemic heart disease 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 Office 12 2,177 $75,887
Injection, denosumab, 1 mg J0897 Office 21 1,501 $31,332
Injection, ferric carboxymaltose, 1 mg J1439 Office 16 13,504 $11,785
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 Office 12 310 $10,845
Injection, zoledronic acid, 1 mg J3489 Office 15 65 $318
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 22 2,325 $247
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 80 236 $210
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 61 1,292 $114
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 60 129 $82
Infusion, normal saline solution , 1000 cc J7030 Office 13 35 $71

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 73 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $535
$535 — —
RYBREVANT
  • Janssen Biotech, Inc. $93
$93 — —
JAKAFI
  • Incyte Corporation $82
$82 — —
TALVEY
  • Janssen Biotech, Inc. $70
$70 — —
TECVAYLI
  • Janssen Biotech, Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 73 with Patron

Records

618 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record